The risk of heart attack and stroke declines, but gastrointestinal problems and joint inflammation increase: New research has shed more light on the pros and cons of weight-loss jabs.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online January ...

You’ll work with your healthcare provider to learn about the best and worst foods to eat while on a GLP-1 weight loss ...

Competition in the ever-growing market for obesity treatments continues to mount, with positive early data for Hong Kong’s ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders.

Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the ...

In December 2024, the Centers for Medicare & Medicaid Services (CMS) formally approved a new quality measure developed by the ...

Ozempic burbs. Ozempic face. Ozempic butt. Ozempic for kids. Everywhere you turn, Ozempic and its related semaglutide drugs, from Wegovy to Mounjaro, are there promising easy weight loss. And as the ...

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a ...

GLP-1 medications associated with lower risks of Alzheimer's and heart disease, but higher risks of pancreatitis and kidney ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...